Literature DB >> 17114492

Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.

Keith K B Gorden1, Xiaohong Qiu, John J L Battiste, Paul P D Wightman, John P Vasilakos, Sefik S Alkan.   

Abstract

Among the 11 human TLRs, a subfamily TLR7, TLR8, and TLR9 display similarities in structure and endosomal localization. Natural agonists consisting of nucleic acids, such as ssRNA or DNA with CpG motifs, activate the innate immune cells through these TLRs. Immune response modifiers (IRMs) of imidazoquinoline class compounds 3M-001, 3M-002, and 3M-003 have been shown to activate the innate immune system via TLR7, TLR8, and TLR7/8, respectively. In looking at the effect of the agonists of the TLR7, TLR8, and TLR9 on the activation of NF-kappaB of transfected HEK cells, we discovered that some oligodeoxynucleotides (ODNs) could modulate imidazoquinoline effects in a negative or positive manner. In this study we demonstrate that poly(T) ODNs can inhibit TLR7 and enhance TLR8 signaling events involving NF-kappaB activation in HEK cells and cytokine production (IFN-alpha, TNF, and IL-12) by human primary PBMC. In contrast, TLR3 agonist poly(I:C) does not affect imidazoquinoline-induced responses. The modulation of TLR7 and TLR8 responses is independent of CpG motifs or the nature of the ODN backbone structure. Furthermore, we show that to be an effective modulator, the ODNs need to be in the cell at the same time with either of the TLR7 or TLR8 agonist. We have also demonstrated that there is a physical interaction between IRMs and ODNs. The cross-talk between ODNs, IRMs, and TLR7 and TLR8 uncovered by this study may have practical implications in the field of microbial infections, vaccination, and tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17114492     DOI: 10.4049/jimmunol.177.11.8164

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

3.  Toll-like receptor signaling controls reactivation of KSHV from latency.

Authors:  Sean M Gregory; John A West; Patrick J Dillon; Chelsey Hilscher; Dirk P Dittmer; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

Review 4.  Innate immune responses regulate morphogenesis and degeneration: roles of Toll-like receptors and Sarm1 in neurons.

Authors:  Hsin-Yu Liu; Chiung-Ya Chen; Yi-Ping Hsueh
Journal:  Neurosci Bull       Date:  2014-07-04       Impact factor: 5.203

5.  Synergistic activation of Toll-like receptor 8 by two RNA degradation products.

Authors:  Matthias Geyer; Karin Pelka; Eicke Latz
Journal:  Nat Struct Mol Biol       Date:  2015-02       Impact factor: 15.369

6.  Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.

Authors:  David N Nguyen; Kerry P Mahon; Ghania Chikh; Phillip Kim; Hattie Chung; Alain P Vicari; Kevin T Love; Michael Goldberg; Steve Chen; Arthur M Krieg; Jianzhu Chen; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

7.  Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Authors:  Joseph A Fraietta; Yvonne M Mueller; Duc H Do; Veronica M Holmes; Mary K Howett; Mark G Lewis; Alina C Boesteanu; Sefik S Alkan; Peter D Katsikis
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

8.  Airway epithelial expression of TLR5 is downregulated in healthy smokers and smokers with chronic obstructive pulmonary disease.

Authors:  Rui Wang; Joumana Ahmed; Guoqing Wang; Ibrahim Hassan; Yael Strulovici-Barel; Jacqueline Salit; Jason G Mezey; Ronald G Crystal
Journal:  J Immunol       Date:  2012-08-01       Impact factor: 5.422

Review 9.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

10.  Clonal dissection of the human memory B-cell repertoire following infection and vaccination.

Authors:  Debora Pinna; Davide Corti; David Jarrossay; Federica Sallusto; Antonio Lanzavecchia
Journal:  Eur J Immunol       Date:  2009-05       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.